Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates ASILOMAR, Calif.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins... Read more

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies ASILOMAR, Calif.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as... Read more

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2024

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference... Read more

Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023. IBO cited Bruker’s double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength. The IBO recognition follows Bruker’s three consecutive years... Read more

Danaher Schedules First Quarter 2024 Earnings Conference Call

WASHINGTON, March 21, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The... Read more

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Novor V2.0 software with novel ML algorithm trained on HLA peptides yields immunopeptidome from de novo peptide sequencing with further improved IDs TwinScape ™ digital-twin technology with iRT ™ standards supports highest timsTOF performance with intelligent feedback – well beyond ‘just up-time’ New glyco-PASEF® method for ultra-high sensitivity 4D glycopeptide analysis Spectronaut® 18 software now... Read more

Bruker Announces Closing of Chemspeed Technologies AG Acquisition

BASEL, Switzerland–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions. This acquisition, first announced in January 2024, marks another significant milestone in Bruker’s expansion in vendor-agnostic scientific software, R&D and QC digitalization,... Read more

Thermo Fisher Scientific to Present at TD Cowen 44th Annual Health Care Conference on March 6, 2024

Thermo Fisher Scientific to Present at TD Cowen 44th Annual Health Care Conference on March 6, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the TD Cowen Health Care Conference on Wednesday, March... Read more

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral... Read more